All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Reid MerrymanThis is the second episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Reid Merryman, Dana-Farber Cancer Institute, Boston, US, Can circulating tumor DNA (ctDNA) help inform on the suitability of autologous stem cell transplantation (auto-SCT) in patients with diffuse large B-cell lymphoma (DLBCL)?
Can ctDNA help inform on the suitability of auto-SCT in patients with DLBCL?
Merryman firstly outlines a strategy for using ctDNA as a prognostic biomarker in patients with DLBCL undergoing auto-STC. Merryman provides supporting data from a study evaluating the prognostic value of ctDNA using an immunoglobulin-based next-generation sequencing technique in patients with DLBCL undergoing auto-STC. He highlights the poor 5-year progression-free survival in patients who were ctDNA-positive within an apheresis stem cell sample. He concludes by outlining the importance of ctDNA as a powerful predictor of relapse; in the future, this tool could be used to guide treatment in patients who are ctDNA-positive.
For the first episode in this series click here.
For the third episode in this series click here.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?